The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC | Common | 00287Y109 | 703,395 | 11,232,758 | SH | DFND | 0 | 11,232,758 | 0 | ||
ALKERMES PLC | Common | G01767105 | 414,134 | 7,451,128 | SH | DFND | 0 | 7,451,128 | 0 | ||
NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 8,638 | 24,815,028 | SH | DFND | 0 | 24,815,028 | 0 | ||
PROTHENA CORP PLC | Common | G72800108 | 507,174 | 10,310,511 | SH | DFND | 0 | 10,310,511 | 0 | ||
THERAVANCE BIOPHARMA INC | Common | G8807B106 | 334,983 | 10,507,608 | SH | DFND | 0 | 10,507,608 | 0 | ||
BIOGEN INC | Common | 09062X103 | 64,918 | 248,530 | SH | DFND | 0 | 248,530 | 0 | ||
GILEAD SCIENCES INC | Common | 375558103 | 43,990 | 614,300 | SH | DFND | 0 | 614,300 | 0 |